Browse the evidence

Multidisciplinary management considerations are offered for clinicians to assist TGD patients with obesity navigate BMI requirements to access GAS.

Clinicians should adopt a multidisciplinary approach to support TGD patients in meeting BMI requirements for GAS.

Static stretching did not significantly interfere with total number of repetitions or total volume of exercise.

Static stretching may not negatively impact overall strength-endurance performance metrics.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT may not be effective, some improvement in menstrual frequency can occur over time.

Semaglutide demonstrated an SAE incidence of 8.9%, compared to 6.2% for Liraglutide.

Practitioners should be aware of the SAE incidence when prescribing these medications.

Discontinuation rates due to adverse effects were 10.3% for Semaglutide and 8.3% for Liraglutide.

Practitioners should consider these discontinuation rates when evaluating treatment options.

GLP-1a therapy was associated with a mean change in body mass index (BMI) of −0.83 kg/m2 in treated patients compared to −0.70 kg/m2 in those without GLP-1a therapy.

GLP-1a therapy may lead to modest reductions in BMI in a real-world setting.

In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs.

Practitioners should be aware that real-world outcomes may differ from clinical trial results.

81.5% of patients achieved excess weight loss (EWL) ≥50% and 51.1% achieved EWL ≥70% during follow-up.

Surgeons can expect a significant proportion of patients to achieve substantial weight loss post-surgery.

Laparoscopic Roux-en-Y gastric bypass (LRYGB) results in higher rates of sustained excess weight loss compared to laparoscopic sleeve gastrectomy (LSG).

LRYGB may be a more effective option for patients seeking long-term weight loss.

A greater proportion of AOM-naïve patients achieved ≥15% and ≥20% total body weight loss at 12 months compared to non-AOM-naïve patients.

Clinicians should note that AOM-naïve patients are more likely to achieve significant weight loss with semaglutide.

Obesity is a major public health problem with a prevalence increasing at an alarming rate worldwide.

Health practitioners should prioritize addressing obesity as a critical public health issue.

The effectiveness of currently approved anti-obesity drugs and other therapeutic avenues is reviewed.

Healthcare providers should stay informed about the effectiveness of anti-obesity medications.

Several agencies have approved tirzepatide for the treatment of type 2 diabetes and obesity.

Tirzepatide is a viable treatment option that is recognized by regulatory agencies for managing type 2 diabetes and obesity.

Brown adipose tissue (BAT) is identified as a thermogenic organ in human adults, which may be targeted for obesity and cardiometabolic disease treatment.

Activating BAT could be a novel strategy for treating obesity and related diseases.

Integrating shared decision-making (SDM) into obesity management enhances patient-centered care and has the potential to improve long-term outcomes.

Practitioners should consider incorporating SDM to enhance patient engagement and outcomes in obesity care.

Programs incorporating SDM reported improved patient engagement, satisfaction, and health outcomes across diverse demographic groups.

Incorporating SDM can lead to better patient experiences and outcomes in obesity management.

Common facilitators of SDM success include the use of decision aids, culturally tailored counseling, and multidisciplinary team involvement.

Healthcare providers should utilize decision aids and culturally tailored approaches to enhance SDM in obesity care.

Distant teams lost similar amounts of weight in all 3 arms but did not keep it off during maintenance.

Interventions may need to address long-term maintenance strategies for participants like Distant teams.

Non-genetic factors are involved in determining body weight and body composition.

Practitioners should consider non-genetic factors when addressing body weight and composition.

Associations between obesity and health are likely causal.

Understanding that obesity has likely causal links to health can guide interventions.

Optimal selection of anti-obesity therapy requires consideration of patient factors and medication-related factors.

Healthcare providers should assess individual patient needs when prescribing anti-obesity medications.

The expanding array of anti-obesity medications provides valuable treatment options alongside lifestyle interventions and surgical approaches.

Integrating medications with lifestyle changes and surgical options can enhance obesity management.

Semaglutide is the most cost-effective treatment option in the severe obesity patient population and in first-tier cities in China.

In specific urban populations with severe obesity, semaglutide may be a preferred treatment option.

Lifestyle management was the most likely to be cost-effective under the willingness-to-pay threshold.

Lifestyle interventions should be prioritized for cost-effective obesity management.